United States biological products, excluding disgnostic substances industry landscape illustrating listed-company operations, infrastructure and market activity

Prism Finance USA · comparison snapshot

Biological Products, Excluding Disgnostic Substances Stocks in USA: Revenue Cohort 3

Name: Biological Products, Excluding Disgnostic Substances Stocks in USA: Revenue Cohort 3 comparison snapshot
Creator: Fliar BI Prism

A five-company biological products, excluding disgnostic substances cohort selected by latest filing revenue, then compared across market path, filings, profitability, readiness, Prism attention and industry context.

Snapshot: 28 August 2026Not investment adviceRanked by Prism readiness

Readiness leaderKrystal Biotech · 54

Strongest available pathADMA Biologics · +607.5%

Widest latest marginKrystal Biotech · 52.6%

Companies compared5 · U.S.-listed

01 · Readiness ranking

Five companies, one comparable score

Companies are ordered by the Fliar BI Prism readiness score used by the Prism Finance USA source pack. The score is a research signal, not a recommendation.

Readiness #1KRYS · Nasdaq

Krystal Biotech

A U.S.-listed issuer classified by the SEC in Biological Products, Excluding Disgnostic Substances

Founded 2015Pittsburgh, Pennsylvania$10.40B market cap

View full Companies Radar profile

54Moderate

Snapshot price$351.5as of page date

Monthly-close return+516.9%five-year window

FY2025 revenue$0.39BKrystal Biotech, Inc.

Net margin52.6%FY2025

P/E snapshot44.0xone ratio, not a verdict

Prism attention16.2%share across these five

Filing track recordRevenue, USD billions

+667.5%

FY2023–FY2025 · 3 filing periods · TOTAL REVENUE · Normalized revenue metric from the in-house filings extraction · CAGR 177.0%

52-week position87% through range

$136.7$382.5

News mentions1.0K

Community mentions0partial coverage

U.S.-scope patents172

Prism InsightsWhat sits behind the readiness signal
Observed risk 0/100higher means more observed risk

Earnings signal83/100
Management stability90/100
Market position0/100
Capital-event signal67/100
Innovation pulse5/100

Management signal

No leadership-churn flag in the model; 0 key-person events recorded in the latest 360-day window.

Market activity

Available history contains 0 M&A involvements, 0 asset-acquisition events and 0 contract events.

Innovation activity

Prism records 0 lifetime product-launch events, 0 in the latest 360 days, and 0 company announcements in that window.

Recent risk watch

No lawsuit or regulatory event is recorded in the latest 360-day window and no layoff event in the latest 180-day window. This is not legal clearance.

Prism model components and available company-event evidence; scores are research signals, not recommendations. Event totals describe available coverage and may not be exhaustive.

Readiness #2ADMA · Nasdaq

ADMA Biologics

A U.S.-listed issuer classified by the SEC in Biological Products, Excluding Disgnostic Substances

Founded 2005Ramsey, New Jersey$2.09B market cap

View full Companies Radar profile

50Moderate

Snapshot price$9.34as of page date

Monthly-close return+607.5%five-year window

FY2025 revenue$0.51BADMA BIOLOGICS, INC.

Net margin28.8%FY2025

P/E snapshot13.3xone ratio, not a verdict

Prism attention10.8%share across these five

Filing track recordRevenue, USD billions

+530.3%

FY2021–FY2025 · 5 filing periods · TOTAL REVENUE · Normalized revenue metric from the in-house filings extraction · CAGR 58.4%

52-week position16% through range

$7.21$20.46

News mentions672

Community mentions0partial coverage

U.S.-scope patents51

Prism InsightsWhat sits behind the readiness signal
Observed risk 0/100higher means more observed risk

Earnings signal51/100
Management stability90/100
Market position18/100
Capital-event signal72/100
Innovation pulse15/100

Management signal

No leadership-churn flag in the model; 0 key-person events recorded in the latest 360-day window.

Market activity

Available history contains 7 M&A involvements, 5 asset-acquisition events and 3 contract events.

Innovation activity

Prism records 0 lifetime product-launch events, 0 in the latest 360 days, and 0 company announcements in that window.

Recent risk watch

No lawsuit or regulatory event is recorded in the latest 360-day window and no layoff event in the latest 180-day window. This is not legal clearance.

Prism model components and available company-event evidence; scores are research signals, not recommendations. Event totals describe available coverage and may not be exhaustive.

Readiness #3TWST · Nasdaq

Twist Bioscience

A U.S.-listed issuer classified by the SEC in Biological Products, Excluding Disgnostic Substances

Founded 2013Dover$8.87B market cap

View full Companies Radar profile

48Cautious

Snapshot price$141.4as of page date

Monthly-close return+35.2%five-year window

FY2025 revenue$0.38BTwist Bioscience Corp

Net margin-20.6%FY2025

P/E snapshot-223.2xone ratio, not a verdict

Prism attention30.0%share across these five

Filing track recordRevenue, USD billions

+184.6%

FY2021–FY2025 · 5 filing periods · TOTAL REVENUE · Normalized revenue metric from the in-house filings extraction · CAGR 29.9%

52-week position89% through range

$23.30$155.4

News mentions1.9K

Community mentions75partial coverage

U.S.-scope patents659

Prism InsightsWhat sits behind the readiness signal
Observed risk 0/100higher means more observed risk

Earnings signal60/100
Management stability85/100
Market position6/100
Capital-event signal69/100
Innovation pulse7/100

Management signal

No leadership-churn flag in the model; 0 key-person events recorded in the latest 360-day window.

Market activity

Available history contains 1 M&A involvements, 1 asset-acquisition events and 8 contract events.

Innovation activity

Prism records 5 lifetime product-launch events, 0 in the latest 360 days, and 3 company announcements in that window.

Recent risk watch

No lawsuit or regulatory event is recorded in the latest 360-day window and no layoff event in the latest 180-day window. This is not legal clearance.

Prism model components and available company-event evidence; scores are research signals, not recommendations. Event totals describe available coverage and may not be exhaustive.

Readiness #4VCEL · Nasdaq

Vericel Corporation

A U.S.-listed issuer classified by the SEC in Biological Products, Excluding Disgnostic Substances

Founded 1989PLYMOUTH$2.10B market cap

View full Companies Radar profile

47Cautious

Snapshot price$40.95as of page date

Monthly-close return-24.0%five-year window

FY2025 revenue$0.28BVericel Corp

Net margin6.0%FY2025

P/E snapshot85.3xone ratio, not a verdict

Prism attention14.8%share across these five

Filing track recordRevenue, USD billions

+80.5%

FY2021–FY2025 · 5 filing periods · TOTAL REVENUE · Normalized revenue metric from the in-house filings extraction · CAGR 15.9%

52-week position59% through range

$28.95$49.32

News mentions920

Community mentions0partial coverage

U.S.-scope patents26

Prism InsightsWhat sits behind the readiness signal
Observed risk 0/100higher means more observed risk

Earnings signal65/100
Management stability90/100
Market position0/100
Capital-event signal55/100
Innovation pulse5/100

Management signal

No leadership-churn flag in the model; 0 key-person events recorded in the latest 360-day window.

Market activity

Available history contains 0 M&A involvements, 0 asset-acquisition events and 0 contract events.

Innovation activity

Prism records 0 lifetime product-launch events, 0 in the latest 360 days, and 0 company announcements in that window.

Recent risk watch

No lawsuit or regulatory event is recorded in the latest 360-day window and no layoff event in the latest 180-day window. This is not legal clearance.

Prism model components and available company-event evidence; scores are research signals, not recommendations. Event totals describe available coverage and may not be exhaustive.

Readiness #5ADPT · Nasdaq

Adaptive Biotechnologies

A U.S.-listed issuer classified by the SEC in Biological Products, Excluding Disgnostic Substances

Founded 2009Seattle, Washington$4.02B market cap

View full Companies Radar profile

34Cautious

Snapshot price$25.19as of page date

Monthly-close return-27.2%five-year window

FY2025 revenue$0.28BAdaptive Biotechnologies Corp

Net margin-21.5%FY2025

P/E snapshot-136.4xone ratio, not a verdict

Prism attention28.2%share across these five

Filing track recordRevenue, USD billions

+79.5%

FY2021–FY2025 · 5 filing periods · TOTAL REVENUE · Normalized revenue metric from the in-house filings extraction · CAGR 15.7%

52-week position89% through range

$12.00$26.87

News mentions1.7K

Community mentions28partial coverage

U.S.-scope patents351

Prism InsightsWhat sits behind the readiness signal
Observed risk 0/100higher means more observed risk

Earnings signal40/100
Management stability90/100
Market position3/100
Capital-event signal25/100
Innovation pulse0/100

Management signal

No leadership-churn flag in the model; 0 key-person events recorded in the latest 360-day window.

Market activity

Available history contains 1 M&A involvements, 0 asset-acquisition events and 1 contract events.

Innovation activity

Prism records 0 lifetime product-launch events, 0 in the latest 360 days, and 0 company announcements in that window.

Recent risk watch

No lawsuit or regulatory event is recorded in the latest 360-day window and no layoff event in the latest 180-day window. This is not legal clearance.

Prism model components and available company-event evidence; scores are research signals, not recommendations. Event totals describe available coverage and may not be exhaustive.

02 · Side-by-side

The comparisons that change the picture

Every bar preserves its own meaning. Price return, revenue scale, profitability and attention are deliberately not blended into one recommendation.

Available monthly-close return

Dated window printed on each company card; not a forecast.

ADMA Biologics

+607.5%

Krystal Biotech

+516.9%

Twist Bioscience

+35.2%

Vericel Corporation

-24.0%

Adaptive Biotechnologies

-27.2%

Latest revenue

USD billions, official filing scope shown on each company card.

ADMA Biologics

$0.51B

Krystal Biotech

$0.39B

Twist Bioscience

$0.38B

Adaptive Biotechnologies

$0.28B

Vericel Corporation

$0.28B

Latest profit margin

Company-card labels distinguish continuing-operations and net-income scope.

Krystal Biotech

52.6%

ADMA Biologics

28.8%

Vericel Corporation

6.0%

Twist Bioscience

-20.6%

Adaptive Biotechnologies

-21.5%

Prism news attention

Normalized share across these five names; attention is not quality.

Twist Bioscience

30.0%

Adaptive Biotechnologies

28.2%

Krystal Biotech

16.2%

Vericel Corporation

14.8%

ADMA Biologics

10.8%

03 · Prism readout

What the signals say—and what they do not

The headline share is normalized biological products, excluding disgnostic substances news attention across these five names. Partial community coverage and U.S.-scope patent records are displayed separately and are not blended into it.

Scale + attention

Twist Bioscience leads the conversation

It holds 30.0% of measured biological products, excluding disgnostic substances news attention and also carries the basket's largest revenue base at $0.38B.

Price path

ADMA Biologics leads the available price paths

Its monthly-close return is +607.5% for the five-year window. At the other end, Adaptive Biotechnologies is -27.2% for its five-year window. Windows printed on each card must be compared carefully; price history is not a forecast.

Profitability

Krystal Biotech has the widest latest margin

Its FY2025 net margin is 52.6%. Its revenue history in this snapshot spans only the periods printed on its card, so longer histories are not treated as equivalent.

Price vs operating signals

Twist Bioscience shows why one ratio is not a verdict

It has the basket's lowest snapshot P/E at -223.2x while its five-year window price return is +35.2%. Valuation, price path and readiness answer different questions.

04 · Research areas

Deeper Prism readout where coverage is dense

Shown only for companies with more than 800 available Prism news records. Counts describe the available research corpus, not company quality.

Areas of research · KRYS

Krystal Biotech

1,006available Prism news records

Prism top themes

Price action & investor response

105

Capital allocation & transactions

Earnings & financial performance

Legal, arbitration & regulatory

Leadership & governance

Mapped subcategory tag occurrences; one article may contribute more than one tag. Since 2024-01-01.

News-volume growth

+65.2%294 latest 12m vs 178 prior 12m

Machine-classified coverage tone

93.1% positive+1.4 pp vs preceding four quarters

24Q3

24Q4

25Q1

25Q2

25Q3

25Q4

26Q1

26Q2

Tone of available coverage, not business performance or an investment outlook.

Frequent keywords

stock performance 43stock price 39biotech incubator 32gene therapy rare diseases 31stock surge 15share price 12company valuation 11stock movement 11

Keyword tag occurrences in available Prism news records.

Coverage: 2016-02-01–2026-06-13 · trend and themes shown through 2026-06

Areas of research · TWST

Twist Bioscience

1,858available Prism news records

Prism top themes

Earnings & financial performance

Price action & investor response

Capital allocation & transactions

Leadership & governance

Legal, arbitration & regulatory

Mapped subcategory tag occurrences; one article may contribute more than one tag. Since 2024-01-01.

News-volume growth

+15.4%314 latest 12m vs 272 prior 12m

Machine-classified coverage tone

91.1% positive-3.6 pp vs preceding four quarters

24Q3

24Q4

25Q1

25Q2

25Q3

25Q4

26Q1

26Q2

Tone of available coverage, not business performance or an investment outlook.

Frequent keywords

diagnostic biotechnology 41synthetic biology 40enzyme engineering 24earnings report 22gene delivery systems 22crispr-cas9 15pharmacogenomics 15stock performance 15

Keyword tag occurrences in available Prism news records.

Coverage: 2010-12-18–2026-06-12 · trend and themes shown through 2026-06

Areas of research · VCEL

Vericel Corporation

920available Prism news records

Prism top themes

Earnings & financial performance

Price action & investor response

Capital allocation & transactions

Leadership & governance

Legal, arbitration & regulatory

Mapped subcategory tag occurrences; one article may contribute more than one tag. Since 2024-01-01.

News-volume growth

-61.6%123 latest 12m vs 320 prior 12m

Machine-classified coverage tone

90.8% positive-5.1 pp vs preceding four quarters

24Q3

24Q4

25Q1

25Q2

25Q3

25Q4

26Q1

26Q2

Tone of available coverage, not business performance or an investment outlook.

Frequent keywords

stem cell banking 38cell-based therapies 15cell therapy 13stock performance 13biosimilar market entry 8stem cell transplantation 8gene therapy rare diseases 7pluripotent stem cells 7

Keyword tag occurrences in available Prism news records.

Coverage: 2010-10-30–2026-06-09 · trend and themes shown through 2026-06

Areas of research · ADPT

Adaptive Biotechnologies

1,746available Prism news records

Prism top themes

Price action & investor response

154

Earnings & financial performance

Capital allocation & transactions

Legal, arbitration & regulatory

Leadership & governance

Mapped subcategory tag occurrences; one article may contribute more than one tag. Since 2024-01-01.

News-volume growth

+91.8%422 latest 12m vs 220 prior 12m

Machine-classified coverage tone

94.9% positive+0.1 pp vs preceding four quarters

24Q3

24Q4

25Q1

25Q2

25Q3

25Q4

26Q1

26Q2

Tone of available coverage, not business performance or an investment outlook.

Frequent keywords

stock performance 58stock price 27adc therapeutics 20immunotherapy 17diagnostic biotechnology 14earnings report 13cancer biomarkers 12synthetic biology 11

Keyword tag occurrences in available Prism news records.

Coverage: 2012-01-03–2026-06-12 · trend and themes shown through 2026-06

05 · Community discussion

Common topics where conversation clears the gate

Shown only above 25 entity-matched mentions. Coverage is partial and topic counts exclude identified namesake noise.

TWST

Twist Bioscience

75 mentions

Stock and valuation

Products, pricing and logistics

Workplace and hiring

Partial entity-matched community coverage; namesake noise is excluded before topic aggregation. 75 records remained after filtering.

ADPT

Adaptive Biotechnologies

28 mentions

Products, pricing and logistics

Stock and valuation

Partial entity-matched community coverage; namesake noise is excluded before topic aggregation. 28 records remained after filtering.

06 · Company event log

Common news types and recent highlights

Event patterns and selected recent headlines come from available Prism company-event records since 2023. Obvious forecast, holdings, duplicate and retrospective noise is filtered.

KRYS

Krystal Biotech

through 2026-05-04

Earnings releases 32Leadership changes 2Listing / IPO 2Company announcements 1Regulatory 1

2026-05-04
Earnings releases
Romano reported net income of $55.9 million for the quarter, or $1.91 per basic share and $1.83 per diluted share, compared to net income of $35.7 million a year earlier.
2025-02-14
Listing / IPO
Krystal Biotech Inc. commenced a public offering of $60 million.
2024-02-27
Regulatory
Despite obtaining FDA approval for treating Dystrophic Epidermolysis Bullosa (DEB), there’s no guarantee of similar regulatory green lights elsewhere, which casts a shadow on their operational outcomes.

Prism company-event records; exact duplicates and evident forecast, holdings and retrospective noise are excluded.

ADMA

ADMA Biologics

through 2026-01-20

Earnings releases 33Lawsuits 5Company announcements 2Leadership changes 2Listing / IPO 2

2026-01-20
M&A
Cerity Partners LLC grew its holdings in ADMA Biologics by 1.8% in the 2nd quarter. Cerity Partners LLC now owns 48,572 shares of the biotechnology company’s stock valued at $884,000 after buying an additional 869 shares in the last quarter.
2026-01-13
Earnings releases
Grossman also provided preliminary, unaudited full-year 2025 expectations of greater than $510–$511 million in revenue, $235 million of EBITDA, and greater than $158 million of net income.
2025-04-07
Company announcements
ADMA Biologics, Inc. (Nasdaq: ADMA) (“ADMA” or the “Company”), an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty biologics, today provided a statement on the recent tariffs put in place and reiterated ADMA’s strategic advantage through fully U.S.-based manufacturing operations, commercialization and end-market sales, and a vertically integrated U.S.-based supply chain.

Prism company-event records; exact duplicates and evident forecast, holdings and retrospective noise are excluded.

TWST

Twist Bioscience

through 2026-05-04

Earnings releases 40Leadership changes 5Company announcements 4Asset acquisitions 1Board updates 1

2026-05-04
Earnings releases
Twist Bioscience Corporation (NASDAQ: TWST ), a mid-cap growth and value biotech company, today announced financial results and business highlights for the second quarter fiscal 2026 ended March 31, 2026.
2026-02-11
Board updates
Stockholders voted on the election of three directors to serve until the 2029 annual meeting of stockholders (and until their successors are elected and qualified, or until earlier resignation or removal). The nominees were Keith Crandell , Jan Johannessen , and Trynka Shineman Blake.
2025-11-14
Company announcements
The company is seeing significant growth in AI-enabled drug discovery, with orders from AI discovery projects growing by more than $25 million compared to fiscal 2024.

Prism company-event records; exact duplicates and evident forecast, holdings and retrospective noise are excluded.

VCEL

Vericel Corporation

through 2026-01-13

Earnings releases 28Leadership changes 2Listing / IPO 1

2026-01-13
Earnings releases
Total net revenue expected to be approximately $276 million , with MACI ® net revenue of $239.5 million and Burn Care net revenue of $36.5 million
2025-02-14
Listing / IPO
BOSTON – Cambridge, Mass.-based Vericel Corp. reported the closing of an underwritten public offering of more than 5.7 million shares of its common stock at a price of $13 per share. The gross proceeds, expected to be about $74.8 million, will be used for general corporate purposes and to expand its business by in-licensing or acquiring assets.
2024-07-22
Leadership changes
CAMBRIDGE, Mass., July 22, 2024 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced the appointment of Karen Mahoney as Chief Human Resources Officer following the retirement of Heidi Hassen.

Prism company-event records; exact duplicates and evident forecast, holdings and retrospective noise are excluded.

ADPT

Adaptive Biotechnologies

through 2026-02-07

Earnings releases 39Company announcements 3Listing / IPO 1M&A 1

2026-02-07
Earnings releases
Piskel reported fourth-quarter total revenue of $71.7 million and full-year revenue of $277 million, representing 51% and 55% year-over-year growth, respectively.
2025-02-14
Listing / IPO
Adaptive Biotechnologies Inc., of Seattle, has filed to raise up to $230 million in an IPO.
2024-04-03
Company announcements
The company will also restructure each business with dedicated resources and separate segment reporting.

Prism company-event records; exact duplicates and evident forecast, holdings and retrospective noise are excluded.

07 · Industry landscape

Biological Products, Excluding Disgnostic Substances Industry in USA

A bottom-of-page sector lens combining Prism's exact U.S. market-growth extraction with tightly matched U.S.-primary biological products, excluding disgnostic substances news. It adds context to the stock basket without turning industry signals into a recommendation.

Prism market forecast extraction

biologics market

26 sources67.0% extraction confidence

2020 extracted base$194.20B–$477.15B

2033 extracted forecast$685.30B–$1.37T

Implied source CAGR8.5%

high demand for the treatment of different disease indicationsTechnologyadvancements in biotechnology

Multi-source card returned by Prism's /special_extraction market-growth service. Extracted geography mix: Global, Asia Pacific, North America, Mexico. This is a dated market benchmark, not a forecast for the five-stock basket.

Prism news insights

U.S. Biological Products, Excluding Disgnostic Substances news pulse

24,998available Prism news records

Latest 12m volume+9.8%10786 vs 9825 records

Positive classified tone41.7%+4.6 pp vs prior four quarters

24Q4

25Q1

25Q2

25Q3

25Q4

26Q1

26Q2

26Q3

Available U.S.-primary Prism records matching biological, disgnostic, excluding, substance, biologic. Metadata counts can overlap; coverage volume and tone are not measures of industry output.

Recurring Prism themes

harm reduction strategies

4,078

substance abuse education

3,736

opioid addiction and treatment

3,643

overdose prevention techniques

3,482

controlled substance regulations

3,381

substance abuse overdose fatalities

3,287

Metadata occurrences; one record can contribute more than one theme.

Frequent industry keywords

mind-altering drug consumption 1,795opioid diversion abuse 1,702fentanyl treatment programs 1,649drug overdose 1,576cannabis policy reform discussions 1,328psychedelic mental health studies 1,328medication-assisted treatment opioids 1,265psychoactive drug intake 1,170

Counts cover the matched industry corpus, not the broader company-news totals above.

Curated signal map

Opportunity and caution, side by side

Evidence prompts—not probabilities.

Opportunity · market driver

high demand for the treatment of different disease indications

26 forecast sources

A recurring driver in the extracted market evidence provides a measurable research thread for the sector.

Prism /special_extraction market-growth card

Opportunity · demand

harm reduction strategies

4,078 matched theme records

The largest current Prism news theme shows where sector attention and reported activity are concentrating.

Prism U.S. news metadata

Opportunity · innovation

Innovation and product activity

2,049 matched news records

Technology, product and R&D metadata provide an auditable view of the sector's innovation conversation.

Unique news records matching the curated innovation rule

Caution · market restraint

Biosimilars entering the market

1,542 macro/risk records

The extracted restraint and the measured macro-news pulse belong in the downside research frame.

Prism market-growth restraint plus U.S. news metadata

Caution · news pulse

Coverage growth can reverse

+9.8% news volume

The latest 12 months contain 10,786 matched records versus 9,825 in the previous window.

Available Prism coverage through 2026-05-05

Caution · sentiment

Classified tone is not demand

41.7% positive · +4.6pp

Machine-classified news tone is useful context, but it is not revenue, output or a return forecast.

Eight-quarter Prism sentiment series

Opportunity and caution cards are curated research prompts grounded in the counts shown; they are not probabilities, recommendations or forecasts. News coverage runs 2024-01-01–2026-05-05; the latest quarter may be partial.

Explore the broader U.S. industrial landscape →

08 · Scope and sources

How to read this snapshot

Basket and ranking

Five U.S.-listed issuers classified under SEC SIC 2836 (Biological Products, Excluding Disgnostic Substances), selected as the first five names that pass all live publication gates from the latest filing revenue candidate pool ranked 11–18. Every candidate has complete cached readiness evidence. This is a research cohort, not a recommendation.

Companies are ordered by the Fliar BI Prism readiness score used by the Prism Finance USA source pack. The score is a research signal, not a recommendation.

Evidence used

Official annual filingsFY revenue history and latest profitability
U.S. exchange market snapshotDated price, 52-week range, P/E, market capitalisation and monthly-close return
Fliar BI PrismReadiness, company and industry news, community context and U.S.-scope patent records
Prism market-growth extractionDated third-party Biological Products, Excluding Disgnostic Substances Industry in USA market benchmark with source-count, geography and confidence context

Important: Research and educational information only. Not investment advice, a recommendation, or a live-price service. Market figures are dated as of 28 August 2026.

09 · Final derived analysis

Conclusions, comparisons, anomalies, explanations and decisions

A final evidence-linked synthesis of the metrics already displayed above. Every named company opens its actual Companies Radar profile.

Conclusions

Krystal Biotech leads the readiness ranking

Its Prism readiness score is 54/100, the highest in this five-company comparison.

Open Krystal Biotech in Companies Radar

Scale and margin leadership sit with ADMA Biologics and Krystal Biotech

ADMA Biologics has the largest displayed latest revenue at $0.51B; Krystal Biotech has the widest displayed latest margin at 52.6%.

Open ADMA Biologics in Companies Radar Open Krystal Biotech in Companies Radar

Comparisons

Strongest versus weakest available price path

ADMA Biologics is +607.5% for its five-year window; Adaptive Biotechnologies is -27.2% for its five-year window.

Open ADMA Biologics in Companies Radar Open Adaptive Biotechnologies in Companies Radar

Largest versus smallest displayed revenue base

The latest displayed revenue ranges from $0.51B for ADMA Biologics to $0.28B for Vericel Corporation. Entity and filing-period labels remain visible on the company cards.

Open ADMA Biologics in Companies Radar Open Vericel Corporation in Companies Radar

Anomalies

Adaptive Biotechnologies has the widest attention-readiness rank gap

It ranks #2 by measured news attention (28.2%) and #5 by Prism readiness. The gap is a review flag, not evidence that either measure is wrong.

Open Adaptive Biotechnologies in Companies Radar

Adaptive Biotechnologies shows a price-operating divergence to inspect

Its displayed filing-revenue change is +79.5% while its available monthly-close return is -27.2%. The signs differ, but the two measures cover different windows and do not establish causality.

Open Adaptive Biotechnologies in Companies Radar

Explanations

Attention measures coverage volume, not quality

Twist Bioscience's 30.0% share says it appears most often in the matched Prism corpus. It does not score whether that coverage is favourable or whether the company is investable.

Open Twist Bioscience in Companies Radar

Different windows explain why signals can disagree

Revenue comes from the printed filing periods, price paths use the dated monthly-close windows, and Prism signals use their stated event windows. No causal attribution is made across them.

Research decisions

Verify the readiness leader in Companies Radar

Open Krystal Biotech's company profile and inspect the underlying management, market-activity, innovation and risk evidence before relying on the 54/100 score.

Open Krystal Biotech in Companies Radar

Stress-test the largest divergence before forming a view

Compare Adaptive Biotechnologies's profile with ADMA Biologics's profile, then reconcile the displayed filing and price windows. This is a next-research action, not a buy or sell decision.

Open Adaptive Biotechnologies in Companies Radar Open ADMA Biologics in Companies Radar

Method boundary: These are deterministic comparisons of the displayed snapshot fields. They flag relationships for further research, do not establish causality and are not investment recommendations.